Theme: Targeting the Roots of Cancer

Oncology Research 2017

Renowned Speakers

Oncology Research 2017

Summary

Above the past 7 years, 151 patients with malignant melanoma and Carcinoma are treated with BCG immunotherapy which is an addition to surgical therapy. The direct injection for metastatic melanoma and Carcinoma lesions limited to skin caused in 90% regression of injected lesions and 17% regression of uninfected lesions in immune competent patients. About 25% of these patients remained free of disease for 1 to 6 years. The injections of BCG into nodules of patients with subcutaneous or visceral metastases causeda lower incidence of local control and no long period survivors. Efforts to improve the results of immunotherapy in these patients by palliative surgical resection of large metastatic lesions to lower tumor burden followed by BCG immunotherapy significantly improved the results although many patients still technologically advanced recurrent disease.

 The 10-year survival rate for patients per metastatic melanoma and Carcinoma is less than 10%. Though surgery and radiation therapy have a role in the treatment of metastatic disease, systemic therapy isprovided that treatment for most patients. Single-agent chemotherapy is well known but is associated with response rates of only 5% to 20%.  The mixtureof chemotherapy and biochemotherapy may improve objective response rates but do not extend survival andrelated with greater toxicity. Immunotherapeutic approaches are in high-dose of interleukin-2 are connected with durable responses in a small percentage of patients. Metastatic melanoma continues to beinspiring disease to treat, with an estimated 8,420 associated deaths in the United States in 2008.Further 3 decades when its initial approval by the US Food and Drug Administration (FDA) in 1975, dacarbazine continues to be standard precaution for most patients with this disease. High-dose of interleukin-2 agreed by the FDA in 1998 for metastatic melanoma, benefits a small division of patients. Efforts to improve upon the survival of patients with metastatic disease have met with failure and need for successful new therapies for metastatic melanoma and Carcinoma cannot be overstated.Probably Melanoma cancer of the skin is 32,210 (4%).

Melanoma and Carcinoma Incidence rate across the World Wide

In the world wide the estimated new melanoma and Carcinoma cancer cases for all ages. In 2012 there are 232130 for both males and females. In 2015 there are 250178 for both males and females and the Demographic Change noticed is 18048.

 

Mortality rate for Melanoma and Carcinoma across the World

In world-wide the estimated melanoma and Carcinoma death cancer cases for all ages. In 2012 there are 55488 for both males and females. In 2015 there are 60098 for both males and females and the Demographic Change noticed is 4610.

 

Melanoma and Carcinoma Incidence rate in Australia

In Australia the estimated new melanoma and Carcinoma cancer cases for all ages. In 2012 there are 12265 for both males and females. In 2015 there are 13111 for both males and females and the Demographic Change noticed is 846. 

Mortality due to Melanoma and Carcinoma across the Australia

In Australia the estimated melanoma and Carcinoma death cancer cases for all ages are: In 2012 there are 1642 for both males and females. In 2015 there are 1775 for both males and females and the Demographic change noticed is 133.

 

Melanoma and Carcinoma Conference Highlights:

Melanoma and Carcinoma Cause

Melanoma Types

Carcinoma Types

Melanoma and Carcinoma Diagnosis

Melanoma and Carcinoma Treatment and Therapy

Melanoma and Carcinoma Laboratory Diagnostic Tests

Melanoma and Carcinoma Advance research

Melanoma and Carcinoma Cancer nanotechnology

Melanoma and Carcinoma  Biomarkers

 

Scope and Importance

The Melanoma EpiCast Report brings an overview of the risk factors, comorbidities, and the global and earlier trends for melanoma of the skin in the eight major markets (US, France, Germany, Italy, Spain, UK, Japan, and Australia). It involves10-year epidemiological forecast for the diagnosed incident cases of melanoma of the skin, segmented by age, sex, and cancer growthperiod at diagnosis (American Joint Commission on Cancer [AJCC] stages I, II, III, and IV). The estimation also includes a 10-year epidemiological calculation for the five-year diagnosed predominant cases and the five-year diagnosed prevalent cases segmented by genetic aberrations (BRAF and c-KIT) in these markets.

The melanoma epidemiology explosion is written and developed by Mastersand PhD-level epidemiologists.The Epicast Report is thorough, high quality, transparent and market-driven, provided that expert analysis of disease trends in the eight major markets.

 

Why it’s in Brisbane Australia?

Brisbane has gained the exactly 1,500 of the world’s leading Melanoma and skin cancer specialists. Queensland has the exciting incidence of skin cancer in the world. Every year skin cancers report for 80% of all newly analysed cancers, with medical practitioners given that more than one million patient consultations resulting in a significant burden on the state’s health care system.Now the 9th World Congress of Melanoma held at the Brisbane Convention & Exhibition Centre (BCEC)in October 2017, given a certain global platform for the world’s foremostscholars, skin cancer specialists and medical professionals.Sight-seeing and Events of Queensland and Brisbane Marketing also played a significant roles in securing the four day conference for Brisbane.Success in securing the return of the Congress to Australian shores for just the second time in 20 years is testimony to Brisbane’s world class research reputation and active engagement in the area of Melanoma and Melanoma management and will provide an opportunity to showcase the ground breaking work of Queensland based researchers and clinicians.

   Brisbane and Australia are well recognised as world leaders in this area, developing new frontiers in research in skin cancer, its origins and treatment. Queensland has the highest rate of skin cancer in the world and Australia overall has two to three times the rates experienced in Canada, the United States and the United Kingdom. We welcome the opportunity to host this important event to share expertise and drive greater action on local and global skin control Brisbane’s reputation and track record for hosting major international events and its appeal to the international scientific and research sectors.“These events have enormous benefit for Brisbane in financial terms, but also in fostering international collaboration, driving investment and delivering research outcomes.“Brisbane is already recognised as an Asia Pacific conventions hotspot, and that reputation will only grow as the city gears up for the G20 World Leaders Summit in November 2014.

      Brisbane will also play host to cancer experts from around the world this November (21-24) at the first ever global skin cancer conference hosted by Cancer Council Queensland. Global Controversies and Advances in Skin Cancer to be held at the BCEC will provide a forum for international, cutting edge debate across prevention, diagnosis, treatment, management and survivorship for all types of skin cancer.

 

Why to Attend?

Informative public with recent advances in Melanoma Cancer diagnosis and therapy from around the world focused on cancer about recent advances in Melanoma Cancer diagnosis and therapy, this is your single best opportunity to reach the largest assemblage of participants .World-renowned speakers, the most recent techniques, and the newest updates in Melanoma Cancer research fields are hallmarks of this conference.

 

Members Associated with Melanoma and Carcinoma Research

In Melanoma and Carcinoma research the members associated are in Worldwide 965 members associated. In Australia 362 members are associated. In Brisbane 143 members are associated.

 

·         Reg Richardson - AM FCPA FCIS ACSA Dip CM (Chairman | MIA)

·         Natalie Foster( Surgical Oncology)

·         Professor Helen Rizos - BSc (Hon) PhD

·         Jennifer Elliott - BA, LLB (Hons), MA, FAICD( Acting General Manager)

·         Garry Sladden - BBus CPA FINSA

·      Helen Schmid - RN, RM, DipAppSc, DipMgt, MPH (Project and Business Manager, Cancer Genetic Epidemiology)

·         Dr Sarah-Jane Schramm – PhD

·         Professor John Thompson - AO MBBS BSc(Med) MD FRACS FACS (Executive Director | MIA)

·         Associate Professor Jonathan Stretch - AM D.Phil (Oxon) FRACS (Deputy Director | MIA)

·         Dr Hamideh Shahheydari – PhD (Postdoctoral Fellow)

·         Professor Fran Boyle - AM MBBS (QLD) FRACP PhD

·         Professor Richard Kefford - AM MB BS PhD FRACP

·         Dr Matteo Carlino - BMedSc, MBBS, FRACP

·         Lydia Visintin - R.N, MCaHaemN (Clinical Nurse Consultant)

·         Associate Professor Georgina Long - BSc PhD MBBS FRACP

·         Gayathri St. George - Bmed.Sc, MSc.Med (RHHG) (PhD candidate)

·         Mitchell Stark - BAppSc(hons)

·         Professor Omgo E. Nieweg - MD, PhD

·         Caroline Watts - RN, RM, BA (Hons), MPH (Project Manager, Melanoma Registrar)

·         Associate Professor Sydney Ch’ing - MBBS, PhD, FRACS

·         Dr Robyn Saw - MBBS, FRACS, MS

·         Dr Sarah Welsh - BSc PhD MBChB MRCP (Medical Oncology)

·         Judith Symmons – RN (Research Nurse)

·         Professor Richard Scolyer - BMedSci, MBBS

·         Dr James WIlmott – BSc (Hons) PhD (Postdoctoral Researcher)

·         Dr Kerwin Shannon (Surgeon)

·         Dr Gerald Fogarty - BSc, MBBS, FRANZCR

·         Dr Angela Hong - MBBS MMed FRANZCR PhD

·         Dr Lauren Aoude – PhD

·         Varsha Tembe – PhD

·         Dr Farad (Fred) Azimi - BSc (Med), MBBS, Masters of Surgery

·         Dr Heidi Cameron - MBBS, FRACS

·         Dr Annette Chakera - MD, PhD

·         Dr Anne Cust - PhD, MPH(Hons), BSc, BA

·         Professor Diona Damian – PhD

·         Melanie Doyle – RN

·         Libby Emmett - RN, Onc Cert, MMedSc

·         Dr Stuart Gallagher – PhD

·         Maria Gonzalez - BN BA M.Hlth.Sc

·         Danielle Gibbs (Research Assistant)

·         Dr Kavitha Gowrishankar – PhD

·         Associate Professor Pascale Guitera - FACD PhD

·         Professor Nick Hayward – PhD

·         Professor Peter Hersey - MBBS, FRACP, D.Phil (Oxon)

·         Anna Hoadley - BA, MNurs, Grad Cert (Oncology)

·         Elizabeth Holland - BSc Macquarie University

·         Dr Lodewijka Holtkamp – MD PhD Student

·         Associate Professor T. Michael Hughes - MBBS (Hons I) Sydney, FRACS

·         Dr Peter Johansson – PhD

·         Dr Teresa Lee – PhD

·         Dr Serigne Lo – PhD Senior Statistician, Senior Research Fellow - University of Sydney

·         Professor Graham Mann – PhD

·         Dr Linda Martin - BSc(Med) MBBS(Hons) MMed FACD

·         Professor William McCarthy – AM

·         Dr Catriona McNeil - MBBS BSc(Med) PhD FRACP

·         Dr Alex Menzies - BSc(Med) MBBS (Hons) FRACP

 

 

Hospitals Associated with Melanoma and Carcinoma Research

In Melanoma and Carcinoma research the hospitals associated in Worldwide 720 hospitals are associated. In Australia 492 hospitals are associated. In Brisbane 105 hospitals are associated.

 

Melanoma Research Foundation

Royal Prince Alfred Hospital

Royal Adelaide Hospital

Community Hospitals

UH Ahuja Medical Center

Calvary Health Care Tasmania St John's Campus

Clare Holland House

Mater Hospital

Melanoma International Foundation

Canberra Hospital, Canberra

National Capital Private Hospital

Canberra Eye Hospital

Gold Coast University Hospital

Major Associations for Melanoma and Carcinoma Cancer

In Melanoma and Carcinoma research the Societies associated in Worldwide 395 societies are associated. In Australia 55 societies are associated. In Brisbane 11 societies are associated.

Worldwide Cancer Research Society

  • American Cancer Society

  • Avon Foundation for Women

  • Cancer Research Institute

  • Conquer Cancer Foundation

  • Damon Runyon Cancer Research Foundation

  • The V Foundation for Cancer Research

  • Society for Melanoma Research

  • International Melanoma Working Group

  • BC Cancer Foundation

 

Industries Associated with Melanoma and Carcinoma Research

In Melanoma and Carcinoma research the industries in Worldwide 172 industries are associated. In Australia 19 industries are associated. In Brisbane 5 industries are associated.

  • Roche

  • Pfizer

  • Merck & Co

  • Novartis

  • Bayer

  • GSK

  • Astra Zeneca

  • Avastin

  • Abbott

  • Lilly

  • Takeda

  • Johnson & Johnson

  • Celgene

 

Universities Associated in Melanoma and Carcinoma  Research

In Melanoma and Carcinoma research the Universities associated are in Worldwide 500 Universities are associated. In Australia 36 Universities are associated. In Brisbane 11 universities are associated

  • Melanoma Institute of Australia

  • Australian National University Medical School

  • Macquarie University Australian School of Advanced Medicine

  • Sydney Medical School

  • University of New South Wales Faculty of Medicine

  • Griffith University School of Medicine

  • Bond University Faculty of Health Sciences and Medicine

  • Deakin University

  • University of western Sydney

  • University of Melbourne

  • University of Tasmania

  • Murdoch University

Market Value for Melanoma and Carcinoma Research

The market value of melanoma and Carcinoma research at 2013 is 1.3 billion dollars, in the upcoming ten years the market value may expect to increase 5.64 billion dollars.

 

Market Growth for Melanoma and Carcinoma Research in the last and upcoming ten years

The market growth of melanoma and Carcinoma shows both increase and decrease in the last ten years and also may expected that may increase or decrease in the upcoming ten years in billion dollars.

 

Products of Melanoma and Carcinoma Cancer Market value

The melanoma and Carcinoma products and the product market is mention based on the melanoma and Carcinoma research.

Tafinlar has the market value 17,956 billion dollars in 2014

Mekinist has the market value of 10,707 billion dollars in 2014-2015

 Zelboraf has the market value of 11,076 billion dollars in 2013-2014

Proleukin has the market value of 2,530 billion dollars in 2013-2014

Opdivo has the market value of 2,454 billion dollars in 2015

Amount Funded Research for Melanoma and Carcinoma

For Melanoma and Carcinoma Research Fund Allotment is 33742250

 

Physicians, Researchers and Academicians working on Melanoma and Carcinoma

Globally there are 720 physicians, 995 researchers and 1250 academicians working on Melanoma and Carcinoma .

 

 

 

ConferenceSeries Ltd is glad to welcome all the interested participants to its 8th International Conference on Blood and Oncology Research during June 26-27, 2017 at London, UK. The conference will be organized around the theme “We share something that kills Cancer”. Oncology Research 2017 welcomes the hematologists, immunologists, pathologists, oncologists, research scholars, industrial professionals and student delegates from biomedical and healthcare sectors to be a part of it.

Oncology Research 2017 will be an initiative to find the weapon to fight against the dreadful cancers, to protect and save lives. Discussions will be focused on the different types of cancers, mainly blood cancer possibility of early detection and treatment at the advanced stages of these cancers to prolong life.

Track 1Oncology

Oncology is a branch of medicine that deals with tumours. A medical expert who practices oncology is an oncologist. Oncologists may isolate on the origin of the sort of action provided to treat the cancer. A medical oncologist treats cancer using chemotherapy or other medications, such as targeted therapy. A surgical oncologist eliminates the tumor and nearby tissue during an operation. A radiation oncologist treats cancer using radiation therapy. Gynaecologic oncology is efforts on different cancers of the female reproductive system. Molecular oncology is the study of chemistry of cancer and tumor cell at its molecular cell. Oncologists may divide on the basis of the type of treatment provided to treat the cancer.

Related Conferences: Cancer Conferences | Oncology Conferences | Hematology Oncology Conferences

8th International Conference on Blood and Oncology Research, June 26-28, 2017 London, UK; 16th Oncologists Meeting, April 24-25, 2017, Dubai, UAE; 19th Euro Congress on Cancer Science & Therapy, July 17-19, 2017, Lisbon, Portugal; Oncology & Cancer Conference, May 25-27, 2017, Osaka, Japan; 25th World Cancer Conference, Oct 19-21, 2017, Rome, Italy; Oncologist & Diagnostics Conference, August 28-30, 2017 Brussels, Belgium; World Cancer Congress (WCC-2017), May 19-21, Barcelona, Spain; 9th Molecular Cancer Biomarkers Conference, August 24-25, 2017, Birmingham, UK; NCRI Cancer Conference 5-8 November 2017, Liverpool, UK; Cancer & Tumour Immunology Conference, July 03-05, 2017, Bangkok, Thailand; Hematologic Malignancies: Translating Discoveries to Novel Therapies, May 6-9, 2017, Boston, Massachusetts; Immuno World 2017, Jan 18-20 2017, Miami, US; Pancreatic Cancer 2017, Jun 12-13 2017, London, UK

Track 2Organ Specific Cancer

Cancer is the term given to a collection of related diseases. Numerous malignancies shape strong tumours, which are masses of tissue. Cancer of the blood, for example, leukaemia, for the most part don't shape strong tumor. Cancerous tumours are malignant, which means they can spread into, or invade, nearby tissues. There are various types of cancer most common type of cancer on the list is breast cancer.

Related Conferences: Cancer Conferences | Oncology Conferences | Hematology Oncology Conferences

8th International Conference on Blood and Oncology Research, June 26-28, 2017 London, UK; Oncology & Cancer Conference, May 25-27, 2017, Osaka, Japan;26th World Cancer Convention November 27-28, 2017, Dubai, UAE; 19th Euro Congress on Cancer Science & Therapy, July 17-19, 2017, Lisbon, Portugal; 16th Oncologists Meeting, April 24-25, 2017, Dubai, UAE; AACR Annual Meeting 2017, April 1-5, 2017, Washington, D.C; European Cancer Congress, Jan 27-30 2017, Netherlands, Amsterdam; Frontiers in Cancer Immunotherapy Conference, Feb 27–28 2017, New York City, USA; Cancer & Tumour Immunology Conference, July 03-05, 2017, Bangkok, Thailand; Global Conference on Cancer Therapy, Aug 07-09 2017, Frankfurt, Germany

Track 3: Cancer and Stem Cells

Cancer stem cells (CSCs) are malignancy cells found inside tumours or haematological diseases that have attributes related with typical undifferentiated organisms, particularly the capacity to offer ascent to all cell sorts found in a specific malignancy test.

Stem cell transplants are techniques that re-establish blood-framing undeveloped cells in individuals who have had theirs devastated by the high measurements of chemotherapy or radiation treatment that are utilized to treat certain tumours.

Related Conferences: Cancer Conferences | Oncology Conferences | Hematology Oncology Conferences

8th International Conference on Blood and Oncology Research, June 26-28, 2017 London, UK; 15th World Cancer Convention, November 27-28, 2017 Dubai, UAE; 16th Oncologists Meeting, April 24-25, 2017, Dubai, UAE; 9th Molecular Cancer Biomarkers Conference, August 24-25, 2017, Birmingham, UK; 2nd Gynaecologic Oncology Congress, Aug 28-29, 2017, London, UK; 6th Breast Cancer Conference, Feb 17-19, 2017, Hong Kong, China; Immuno World 2017, Jan 18-20 2017, Miami, US; European Cancer Congress, Jan 27-30 2017, Netherlands, Amsterdam; Cancer & Tumour Immunology Conference, July 03-05, 2017, Bangkok, Thailand; ; NCRI Cancer Conference 5-8 November 2017, Liverpool, UK

Track 4Cancer Causes and Preventions

Metastasis, or metastatic ailment, is the spread of a malignancy or other infection starting with one organ or part then onto the next not specifically associated with it. An oncovirus is an infection that can bring about tumor. This term started from investigations of intensely changing retroviruses, regularly called oncornaviruses to signify their RNA infection beginning. Physical and Chemical Agents are changes the genetic material like DNA of a living beings that can changes the elucidation and interpretation and DNA replication which can drives cell death.

Tumor Vaccines uses to treat the development the disease might exist malignancy or keeps the progression malignancy. Nourishment and disease great sustenance is imperative to the tumor patients its offers quality to the general population. Changes in Lifestyle are likewise aware to increments in the growth rates like smoking drinking no physical action.

Related Conferences: Cancer Conferences | Oncology Conferences | Hematology Oncology Conferences

8th International Conference on Blood and Oncology Research, June 26-28, 2017 London, UK; 11th Leukemia Conference, October 05-06, 2017, London, UK; 2nd Neuro Oncology and Neurosurgery Conference, April 24-25, 2017 Dubai, UAE; 19th Euro Congress on Cancer Science & Therapy, July 17-19, 2017, Lisbon, Portugal; 16th Oncologists Meeting, April 24-25, 2017, Dubai, UAE; 30th Annual Meeting Danish Association for Cancer Research, April 28, 2017, Denmark; European Cancer Congress, Jan 27-30 2017, Netherlands, Amsterdam; Global Conference on Cancer Therapy, Aug 07-09 2017, Frankfurt, Germany; Hematologic Malignancies: Translating Discoveries to Novel Therapies, May 6-9, 2017, Boston, Massachusetts

Track 5: Cancer Diagnosis and Diagnostics

Most tumours are at first perceived either in view of the presence of signs or manifestations or through screening. Neither of these prompts to a complete conclusion, which requires the examination of a tissue test by a pathologist. Individuals with suspected cancer are examined with medicinal tests. Diagnostic testing involves tests and procedures to confirm the presence of cancer and identify the correct tumor type, location, extent and stage. Cancer treatment use sophisticated diagnostic technology to pinpoint and evaluate tumours, and develop a personalized treatment plan.

Related Conferences: Cancer Conferences | Oncology Conferences | Hematology Oncology Conferences

8th International Conference on Blood and Oncology Research, June 26-28, 2017 London, UK; 16th Oncologists Meeting, April 24-25, 2017, Dubai, UAE; 19th Euro Congress on Cancer Science & Therapy, July 17-19, 2017, Lisbon, Portugal; Oncology & Cancer Conference, May 25-27, 2017, Osaka, Japan; 25th World Cancer Conference, Oct 19-21, 2017, Rome, Italy; Oncologist & Diagnostics Conference, August 28-30, 2017 Brussels, Belgium; World Cancer Congress (WCC-2017), May 19-21, Barcelona, Spain; 9th Molecular Cancer Biomarkers Conference, August 24-25, 2017, Birmingham, UK; NCRI Cancer Conference 5-8 November 2017, Liverpool, UK; Cancer & Tumour Immunology Conference, July 03-05, 2017, Bangkok, Thailand; Hematologic Malignancies: Translating Discoveries to Novel Therapies, May 6-9, 2017, Boston, Massachusetts; Immuno World 2017, Jan 18-20 2017, Miami, US; Pancreatic Cancer 2017, Jun 12-13 2017, London, UK

Track 6: Cancer Treatment and Therapeutics

A sort of treatment that utilizations drugs or different substances to recognize and assault particular sorts of cancer cells with less damage to typical cells. Some focused on treatments obstruct the activity of specific compounds, proteins, or different atoms required in the development and spread of growth cells. Different short of targeted therapies help the immune system kill cancer cells or deliver toxic materials directly to cancer cells and kill them. Targeted treatment may have less reactions than different sorts of malignancy treatment. Most focused on treatments are either little particle medications or monoclonal antibodies.

Therapeutics appropriately refers to the utilization of medications and the strategy for their organization in the treatment of cancer. Cancer therapeutics a joined train of medicinal oncology, which might be characterized as the non-surgical, non-radio therapeutic administration of patients with strong tumours and clinical pharmacology, in light of great cytotoxic chemotherapy and the new flag transduction inhibitors.

Related Conferences: Cancer Conferences | Oncology Conferences | Hematology Oncology Conferences

8th International Conference on Blood and Oncology Research, June 26-28, 2017 London, UK; 11th Leukemia Conference, October 05-06, 2017, London, UK; 2nd Neuro Oncology and Neurosurgery Conference, April 24-25, 2017 Dubai, UAE; 19th Euro Congress on Cancer Science & Therapy, July 17-19, 2017, Lisbon, Portugal; 16th Oncologists Meeting, April 24-25, 2017, Dubai, UAE; 30th Annual Meeting Danish Association for Cancer Research, April 28, 2017, Denmark; European Cancer Congress, Jan 27-30 2017, Netherlands, Amsterdam; Global Conference on Cancer Therapy, Aug 07-09 2017, Frankfurt, Germany; Hematologic Malignancies: Translating Discoveries to Novel Therapies, May 6-9, 2017, Boston, Massachusetts

Track 7: Cancer and Pharmacology

Cancer Pharmacology is at the interface of portraying key procedures in growth science and comprehension the systems of activities of specialists that regulate expansion, survival, mutagenesis, and tumorgenesis. Different research methodologies are being utilized and run from present day strategies in cell and atomic science utilizing as a part of vitro model frameworks to in vivo models of carcinogenesis to front line scientific ways to deal with distinguish and measure DNA adducts and transformations. For the most part, a multiplying or more in plasma drug focus the potential for upgraded antagonistic or valuable medication reaction Drug cooperation in oncology are of specific significance attributable to the tight healing list and the immutable lethality of anticancer specialists.

Related Conferences: Cancer Conferences | Oncology Conferences | Hematology Oncology Conferences

8th International Conference on Blood and Oncology Research, June 26-28, 2017 London, UK; 16th Oncologists Meeting, April 24-25, 2017, Dubai, UAE; 19th Euro Congress on Cancer Science & Therapy, July 17-19, 2017, Lisbon, Portugal; Oncology & Cancer Conference, May 25-27, 2017, Osaka, Japan; 25th World Cancer Conference, Oct 19-21, 2017, Rome, Italy; Oncologist & Diagnostics Conference, August 28-30, 2017 Brussels, Belgium; World Cancer Congress (WCC-2017), May 19-21, Barcelona, Spain; 9th Molecular Cancer Biomarkers Conference, August 24-25, 2017, Birmingham, UK; NCRI Cancer Conference 5-8 November 2017, Liverpool, UK; Cancer & Tumour Immunology Conference, July 03-05, 2017, Bangkok, Thailand; Hematologic Malignancies: Translating Discoveries to Novel Therapies, May 6-9, 2017, Boston, Massachusetts; Immuno World 2017, Jan 18-20 2017, Miami, US; Pancreatic Cancer 2017, Jun 12-13 2017, London, UK

Track 8Biomarkers

A cancer biomarker can be a procedure substance that demonstrates the nearness of tumor in the body. It might be a particle discharged by tumor cells or a specific reaction of the body as a result of the nearness of growth. Biomarkers may hereditary, epigenetic, proteomic, glycomic, or imaging. They can be utilized for disease analysis, forecast, medication, the study of disease transmission of malignancy. Those biomarkers that are especially connected with transformations offer a quantitative approach to decide when people are inclined to specific sorts of diseases. In numerous ranges of pharmaceutical, biomarkers are restricted to proteins identifiable or quantifiable in the blood or urine. In any case, the term is frequently used to cover any atomic, biochemical, physiological, or anatomical property that can be evaluated or measured.

Related Conferences: Cancer Conferences | Oncology Conferences | Hematology Oncology Conferences

Track 9Hematology

Hematology involves with the study, diagnosis, treatment, and prevention of diseases related to the blood. The study is based on treating diseases that affect the production of blood and its components, such as blood cells, hemoglobin, blood proteins, bone marrow, platelets, blood vessels, spleen, and the mechanism of coagulation.

Related Conferences: Cancer Conferences | Oncology Conferences | Hematology Oncology Conferences

Track 10Haematologic Oncology

Blood malignancies are forms of cancer that begins in the cells of blood-forming tissue, such as the bone marrow, or in the cells of the immune system. Examples of hematologic cancer are acute and chronic leukaemia, lymphomas, multiple myeloma and myelodysplastic syndromes. Myeloproliferative neoplasms, or MPNs, are hematologic cancers that arise from malignant hematopoietic myeloid progenitor cells in the bone marrow, such as the precursor cells of red cells, platelets and granulocytes. The other types of Blood Malignancies also include sarcoma, lymphodema, Non-Hodgkin lymphoma (NHL) and lymphoma, lymphoid cancer, bone marrow cancer.

Related Conferences: Cancer Conferences | Oncology Conferences | Hematology Oncology Conferences

Track 11Blood Cancer

The cause is usually different from other types of cancer. Experts say that Blood Malignancies arise due to different causes, some of them are suspected and some are yet to be. It is nearly impossible to prove what caused a blood cancer in any individual, because most blood cancers have multiple possible causes.

Discussions will be carried out on the suspecting and suspected causes of blood cancer that include: Exposure to radiation and chemicals, Genetic predisposition, drugs, Human T-cell Leukemia Virus (HTLV), Electromagnetic energy, Genetic factors (chromosomal abnormalities, maternal fetal transmission rare).

Related Conferences: Cancer Conferences | Oncology Conferences | Hematology Oncology Conferences

Track 12Breast Cancer

Breast malignancy begins when cells in the bosom start to become wild. These cells for the most part shape a tumor that can frequently be seen on an x-beam or felt as a knot. The tumor is dangerous (disease) if the cells can develop into (attack) encompassing tissues or spread (metastasize) to inaccessible zones of the body. Bosom growth happens totally in ladies, yet men can get breast cancer, as well.

Hazard elements for creating breast tumor incorporate being female, weight, absence of physical work out, drinking liquor, hormone substitution treatment amid menopause, ionizing radiation, early age at first period, having youngsters late or not in the least, more established age, and family history.

Related Conferences: Cancer Conferences | Oncology Conferences | Hematology Oncology Conferences

Track 13:  Gynaecologic Cancer

A gynecologic oncologist is an obstetrician/gynecologist who works in the analysis and treatment of ladies with tumor of the conceptive organs including ovarian cancer, uterine cancer, vaginal cancer, cervical cancer, and vulvar cancer. With a specific end goal to wind up distinctly a gynecologic oncologist in the United States, a doctor should first entire an endorsed, 4-year residency program in obstetrics and gynecology. Taking after this, he/she should finish a 2–4 year clinical partnership in gynecologic oncology.

Related Conferences: Cancer Conferences | Oncology Conferences | Hematology Oncology Conferences

Track 14Blood Disorders

CBlood Disorder is a condition in which there's an issue with red blood cells, white blood cells, or the littler, circulating cells called platelets, which are basic for cluster arrangement. Each of the three cell sorts shape in the bone marrow, which is the delicate tissue inside bones. Blood disorders can also affect the liquid portion of blood, called plasma.

Related Conferences: Cancer Conferences | Oncology Conferences | Hematology Oncology Conferences

Track 15Immunology

Cancer immunology is a branch of immunology that studies interactions between the immune system and cancer cells (also called tumors or malignancies). It is a growing field of research that aims to discover innovative cancer immunotherapies to treat and retard progression of the disease. The immune response, including the recognition of cancer-specific antigens, is of particular interest in the field as knowledge gained drives the development of targeted therapy (such as new vaccines and antibody therapies) and tumour marker-based diagnostic tests. These scientific sessions will include the discussion on various topics such as Immunotherapeutic approaches, immune tolerance and deficiencies, Anti-Blood Cancer Factor and immunotherapy.

Related Conferences: Cancer Conferences | Oncology Conferences | Hematology Oncology Conferences

Track 16Oncology Nursing and Care

An Oncology Nurse gives care to malignancy patients and those at hazard for getting the malady. They screen physical conditions, recommend solution, and oversee chemotherapy and different medicines. Oncology nursing frequently serves as your first line of correspondence, and help to organize the numerous parts of your care all through growth treatment.

Related Conferences: Cancer Conferences | Oncology Conferences | Hematology Oncology Conferences

Track 17: Cancer Epidemiology

Cancer epidemiology is concerned with the estimation and study of cancer and its prevalence in a certain area of population, to conclude the possible trends, causes of cancer and develop improved treatments by the use of epidemiological methods. Cancer epidemiology is principally concerned with the study of cancer, its causes, detection, and treatment based on the progression of the disease. 

Related Conferences: Cancer Conferences | Oncology Conferences | Hematology Oncology Conferences

Track 18: Clinical Trials and Case Report

A case report is a detailed report consisting the symptoms, signs, diagnosis, treatment, and follow-up of an individual patient. A case report is generally considered a type of evidence of the work carried out and the output attained.

Case studies are extremely useful records of the clinical practices of a profession. They are a record of clinical interactions which help us to frame questions for more rigorously designed clinical studies. Case studies also provide valuable teaching material, demonstrating both classical and unusual presentations which may challenge the practitioner.

Related Conferences: Cancer Conferences | Oncology Conferences | Hematology Oncology Conferences

Track 19: Entrepreneurs Investment Meet

A platform aimed to connect Entrepreneurs, Proposers and the Investors worldwide. It's intended to create and facilitate the most optimized and viable meeting place for engaging people in global business discussions, evaluation and execution of promising business ideas. An investor could be able to find out the highest potential investment opportunities globally, which provide good return on investment. For entrepreneurs, this would be an ideal place to find out suitable investors and partners to start and/or expand their business. Thus it is a perfect place to connect Entrepreneurs, Business Owners, Early Stage Companies and Established Corporates with National or International Investors, Corporate Investors and Potential Business Partners.

Related Conferences: Cancer Conferences | Oncology Conferences | Hematology Oncology Conferences

Market Analysis Report:

Cancer is a disease in which abnormal cells divide uncontrollably and destroy body tissue.  There are more than 100 types of cancer, including breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. Symptoms vary depending on the type. Cancer treatment may include chemotherapy, radiation, and/or surgery.

Cancer is a complex medical issue that requires a multidisciplinary approach. This approach is sweeping and ranges from well-being advancement to counteractive action and screening, diagnosis, treatment, restoration and palliative care.

Importance & Scope

Oncology Research 2017 will be the best platform for all the oncologists, haematologists, research scholars, students who are working in this field to exchange their knowledge related to Blood & Oncology Research. This international event is an effort to understand the underlying biological procedures which are amended to increase effectiveness, precision, survivability, and quality of life.

Specialists will clarify how another era of treatment alternatives gives patients new trust in the battle against cancer.

Geologically, the worldwide cancer treatment market is grouped into locales to be specific, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Middle East, Japan, and Africa. North America takes the biggest share of worldwide cancer growth treatment approximately 42% showcase took after by Europe approx. 26%. The worldwide oncology treatment market is required to develop in future because of expanding venture by multinational organizations in cancer look into.

        

Why London?

London is the capital and most crowded city of England and the United Kingdom with inhabitant populace of 7,500, making it the littlest city in England. Remaining on the River Thames, London has been a noteworthy settlement for two centuries.

London is a main worldwide city, with qualities of heritage, expressions, trade, training, diversion, fashion, fund, innovative work, social insurance, media, proficient administrations and tourism. In UK more than 90 Universities/schools, 200 pharmaceutical organizations, and more than 80 Associations and social orders are taking a shot at Cancer and other blood related scatters. Subsidizing awards by the legislature of china for research almost 200 million USD$ to colleges and 1.5 billion USD$ to the pharmaceutical and research establishments.

Conference Highlights:

·         Oncology

·         Cancer

·         Cancer Causes and Preventions

·         Cancer Diagnosis and Diagnostics

·         Cancer Treatment and Therapeutics

·         Cancer and Pharmacology

·         Biomarkers

·         Hematology

·         Haematologic Oncology

·         Breast Cancer

·         Blood Cancer

·         Blood Disorders

·         Immunology

·         Cancer Epidemiology

·         Clinical Trials and Case Report

·         Entrepreneurs Investment Meet

Why to attend..??

This exceptional universal meeting gives a stage to scientists and leaders in cancer research to display their most recent discoveries and find out about all the imperative advancements in disease investigate. Numerous researchers and widely renowned specialists will participate in the meeting. Over the course of the two day meeting, you will have the chance to both network and hear pioneers from the global scholastic and corporate cancer investigate groups.

Target Audience

Oncology Research 2017 welcomes the oncologists, hematologists, immunologists, pathologists, research scholars, doctors/clinicians, industrial professionals, student delegates and cancer associations & societies from biomedical and healthcare sectors to be a part of it.

       

Major Associations

In London

Cancer Research UK

Children with Cancer UK

United Kingdom Association of Cancer Registries

Children’s Cancer and Leukaemia Group

Leukaemia Cancer Society

Lymphoma Association

Leukaemia & Lymphoma Research

Myeloma UK

Leukaemia CARE

In USA

American Cancer Society (ACS)

Hematology/Oncology Pharmacy Association

Cancer Research Institute, USA

National Cancer Institute (USA)

American Society of Haematology

American Association for Cancer Research (AACR)

Association of International Cancer Research

National Cancer Institute

Lymphoma Research Foundation, USA

National Children’s Leukaemia Foundation, USA

International Myeloma Foundation

National Children's Leukemia Foundation

Childhood Leukemia Foundation

Cancer and Leukemia Group B

International Agency for Research on Cancer (IARC)

Union for International Cancer Control (UICC)

Prevent Cancer Foundation

American Childhood Cancer Organisation

Worldwide

Union for International Cancer Control

International Fanconi Anemia Registry (IFAR)

Armenian Association of Hematology & Oncology

Cancer Association of South Africa

Canadian Cancer Sociey

Society for Paediatric Oncology & Hematology

Chinese Society of Clinical Oncology

Cancer Research UK

Indian Association of blood cancer & Allied Diseases

The Leukaemia and Lymphoma Society of Canada

Leukaemia Cancer Society

Leukaemia & Blood Cancer New Zealand

Korean Cancer Association

Fanconi Anaemia Australia

Leukaemia Foundation of Australia

Indian Cancer Society

Brazilian Lymphoma & Leukaemia Association

Chronic Myelogenous Leukaemia Society of Canada

Children’s Cancer and Leukaemia Group

German Cancer Society

Lymphoma Foundation Canada

Cancer Society of Finland

France Lymphoma Hope

Leukaemia &Blood Cancer, New Zealand

Medical Oncology Group of Australia

Australian & New Zealand Children’s Hematology/Oncology Group

Childhood Cancer Research Group, UK

National Cancer Institute of Argentina

Cancer Society Nepal

      

Top Universities

In London

University of Oxford

University of Cambridge

King's College London

UCL Medical School

Queen Mary, University of London

Imperial College, London

Institute on Cancer Research

St. George’s, University of London

The University of Sheffield

         

In USA

Harvard University

Stanford University

Cambridge University

Mayo Medical School, US

John Hopkins University

Yale University

University of Colorado

St. George’s University

Emory University

University of California

University of Maryland, Baltimore

North-western University, IIlinois

University of Texas

Massachusetts Institute of Technology (MIT)

Carnegie Mellon University, United States of America

University of Pennsylvania, Philadelphia

Indiana University School of Medicine, Melvin and Bren Simon Cancer Center

University of Rochester, New York

Cornell University, United States of America

Baylor COLLEGE of medicine US

Columbia University, New York

University of Iowa

Princeton University, US

University of Minnesota Medical Center

University of Auckland

University of Michigan

University of Melbourne

Ohio State University, Columbus

Rockefeller University, US

Worldwide

University of Chicago, Chicago

University of Toronto, Canada

Washington University in St. Louis

Thomas Jefferson University

National University of Singapore (NUS), Singapore

Indianapolis University “La Sapienza” of Rome, Rome, Italy

University of Wisconsin, Madison-

University of Tokoyo, Japan

Guangxi Medical University, Nanning, China

University of Lyon, France

University Of Leeds

University Of Queensland,Australia

University of Arizona Cancer Center

University of Utah

Georgetown University Medical Center

 University of Southampton

University of Pittsburgh

 McMaster University

University Of Florida

Vanderbilt University School of Medicine

Wayne State University School of Medicine

University of Alberta

University Of British Columbia

University Of Leicester

 University Of Chester

University of Kentucky

University of north Durham

 University Of Surrey

 University Of Edinburgh

 University of Glasgow

 University Of Bordeaux,France

Oregon Health and Science University

 Knight Cancer Institute

Loyola University Chicago

University oF Louisville

 University of Toledo

Rutgers University

University Of Calgary

University Of Witaterstrand

University Of Western Sydney, Australia

University of Melbourne

University Of South Australia

University Of New South Wales

Monash University, Australia

University of Milan, Italy

Kyoto University, Japan

The University of Auckland, NZ

University Of Zurich

National Taiwan University

The University of Manchester, UK

Ichan School of medicine, Mount Sinai

Pondicherry University, India

University of phoenix

Griffith University

University Of Exeter

Crimea State Medical University,Ukriane

 Heidelberg University

 Hackensack University Medical Center

 Kyoto University, Taiwan

 Osaka University, Japan

 Kursk State Medical University, Russia

Companies

Roche group is one of the main suppliers of cancer growth treatment drugs. A portion of the key players in cancer treatment market are Novartis Pharmaceuticals, Celgene Corporation, Merck & Co., Bristol-Myers Squibb Company, AbbVie Inc., Johnson and Johnson Pvt. Ltd., Amgen Inc., Teva pharmaceutical Industries Ltd., Bayer AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd.

Market Analysis report

The market of cancer is communicated to show unfaltering development rate amid the estimate time frame from 2015 – 2020. This development is driven by main considerations, for example, rising predominance of different infections and broad R&D practices are progressing over the globe to bring new and more successful medications and plans in the market.

Progression in innovation customized pharmaceutical, financially savvy treatment methods are couple of different components anticipated to keep up the development of worldwide cancer treatment showcase. However, unique nature of blood diseases and expanding stringency in the administrative prerequisites are a portion of the real restrictions constraining the development of worldwide tumor treatment showcase.

       

The worldwide market for Oncology medications was assessed to be $25.8 billion in 2015. By 2017, the market is relied upon to reach $42.5 billion, developing at a CAGR of 12% in the vicinity of 2015 and 2017. The aggregate worldwide market for oncology issue medications and diagnostics in 2015 was assessed at almost $82.3 billion. By 2017, the market is relied upon to reach $99.3 billion, developing at a compound yearly development rate (CAGR) of 7.2% in the vicinity of 2015 and 2017. The worldwide cancer issue advertise section is evaluated at $53.3 billion in 2015 and is relied upon to reach about $76.7 billion by 2017. The real purpose behind the low development rate is the normal decrease in the yearly cost of treating cancer issue and the patent lapses of Lovenox, Plavix, Procrit/Epogen, Aranesp, and Neulasta. In 2010, every one of these medications together achieved income of $32 billion into the worldwide blood issue advertise.

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date June 26-28, 2017
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity Closed Day 1 Day 2
Poster Opportunity Closed Click Here to View